Investigational drug · Phase 3
Zanzalintinib
Also called: XL092
Not approved by FDA. In 11 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Colorectal Cancer, Renal Cell Carcinoma, Head and Neck Squamous Cell Carcinoma.
Phase 3Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
11
11 still active
All registered trials
47
Any phase or sponsor naming "Zanzalintinib"
First trial start
2022
Sep 7, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Zanzalintinib", any sponsor or status.
Conditions studied
As listed on its trial records.
- Colorectal Cancer
- Renal Cell Carcinoma
- Head and Neck Squamous Cell Carcinoma
- Cancer
- Renal Cell Carcinoma (RCC)
- Pancreatic Neuroendocrine Tumors (pNET)
- Extra-Pancreatic NET (epNET)
- Hepatocellular Carcinoma (HCC)
- Differentiated Thyroid Cancer (DTC)
- Non-Clear Cell Renal Cell Carcinoma (nccRCC)
Approved drugs for the same conditions: Colorectal cancer · Pancreatic cancer · Kidney cancer (renal cell carcinoma) · Liver cancer (hepatocellular carcinoma) · Head and neck cancer · Thyroid cancer · Oncology · Kidney and urology · Gastroenterology and liver · Endocrinology and women's health
Largest trials
Live from ClinicalTrials.gov: studies naming "Zanzalintinib" as an intervention, largest first.
- Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored StudyPivotal-lookingEnrolling by invitation
ExelixisIndustry
NCT07620574 · 5,000 participants (planned) · Start Jul 30, 2026 · Primary completion May 31, 2030
Drug: Cabozantinib; Zanzalintinib and 5 more · For: Cancer; Renal Cell Carcinoma (RCC); Pancreatic Neuroendocrine Tumors (pNET) and 6 more
Sites: Bay Shore, New York; Kettering, Ohio; Memphis, Tennessee · 4 sites in all
- Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid TumorsPivotal-lookingRecruiting
ExelixisIndustry
NCT05176483 · 1,394 participants (planned) · Start Dec 14, 2021 · Primary completion Jan 31, 2027
Drug: Zanzalintinib; Nivolumab and 5 more · For: Renal Cell Carcinoma (RCC); Metastatic Castration-Resistant Prostate Cancer (mCRPC); Urothelial Carcinoma (UC) and 8 more
Sites: Phoenix, Arizona; Tucson, Arizona; Palo Alto, California · 122 sites in all
- A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07227402 · 904 participants (planned) · Start Nov 26, 2025 · Primary completion Feb 27, 2032
Drug: Belzutifan; Zanzalintinib and 1 more · For: Renal Cell Carcinoma
Sites: Anchorage, Alaska; Fullerton, California; Los Angeles, California · 129 sites in all
- A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07489495 · 758 participants (planned) · Start Apr 9, 2026 · Primary completion Nov 27, 2030
Drug: Belzutifan; Zanzalintinib and 1 more · For: Carcinoma, Renal Cell
Sites: Duarte, California; Irvine, California; Marietta, Georgia · 111 sites in all
- Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaPivotal-lookingActive, not recruiting
ExelixisIndustry
NCT06082167 · 600 participants (planned) · Start Jun 7, 2024 · Primary completion Aug 2028
Drug: Zanzalintinib; Zanzalintinib-matched Placebo and 1 more · For: Head and Neck Squamous Cell Carcinoma
Sites: Fullerton, California; Orange City, Florida; Tampa, Florida · 168 sites in all
- Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual DiseasePivotal-lookingRecruiting
ExelixisIndustry
NCT07750158 · 600 participants (planned) · Start Dec 18, 2026 · Primary completion Apr 5, 2030
Drug: Zanzalintinib; Pembrolizumab (+) Berahyaluronidase alfa and 1 more · For: Colorectal Cancer
Sites: Fort Lauderdale, Florida; Lake Mary, Florida; Orlando, Florida · 17 sites in all
- Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine TumorsPivotal-lookingRecruiting
ExelixisIndustry
NCT06943755 · 440 participants (planned) · Start Jul 21, 2025 · Primary completion Jun 30, 2029
Drug: Zanzalintinib; Everolimus · For: Pancreatic Neuroendocrine Tumor (pNET); Extra-Pancreatic Neuroendocrine Tumor (epNET)
Sites: Birmingham, Alabama; Phoenix, Arizona; Tucson, Arizona · 135 sites in all
- A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)Pivotal-lookingTerminated
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT03337698 · 314 participants · Start Dec 27, 2017 · Primary completion Oct 14, 2025
Drug: Atezolizumab; Cobimetinib and 15 more · For: Carcinoma, Non-Small-Cell Lung
Sites: Las Vegas, Nevada; New York, New York; Cleveland, Ohio · 29 sites in all
ExelixisIndustry
NCT06952010 · 303 participants (planned) · Start May 1, 2025 · Primary completion May 31, 2027
Drug: XB628; Zanzalintinib · For: Solid Tumor; Advanced Solid Tumor; Metastatic Solid Tumor and 1 more
Sites: San Francisco, California; New Haven, Connecticut; Tampa, Florida · 11 sites in all
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07049926 · 140 participants (planned) · Start Jul 20, 2025 · Primary completion Oct 26, 2031
Drug: Belzutifan; Zanzalintinib · For: Renal Cell Carcinoma
Sites: San Francisco, California; Mineola, New York; New York, New York · 33 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Reprogramming the tumor microenvironment in MSS CRC: the role of TKIs in combination with immunotherapy.
Venturini J, Rossini D, Conticello C, et al. · ESMO Gastrointest Oncol 2026
- Biomarker-guided treatment selection in metastatic colorectal cancer: A critical review of established and emerging therapies.
Tojjari A, Pourbahrighesmat S, Alkhazna S, et al. · Crit Rev Oncol Hematol 2026
- STELLAR-311: a randomized phase II/III study of zanzalintinib versus everolimus in advanced neuroendocrine tumors.
Chan JA, Strosberg JR, Yoo C, et al. · Future Oncol 2026
- From cabozantinib to zanzalintinib: obvious chemical modifications as a new frontier in product hopping.
Strohbehn GW, Tu SS, Wang X, et al. · Nat Biotechnol 2026
- TWEAK/FN14 inhibition synergizes with oncogene-directed tyrosine kinase inhibitors to overcome resistance across multiple driver contexts.
Weiss GJ, Loftus JC, Mallery DW, et al. · Sci Rep 2026
- Molecular complete response to the RIN protocol (regorafenib, ipilimumab, and nivolumab) in a patient with advanced recurrent metastatic mismatch repair proficient/microsatellite stable (pMMR/MSS) rectal cancer.
Qadri F, Afghan MK, Lutfi A, et al. · Ther Adv Med Oncol 2026
Also in development for Colorectal Cancer
- BL-M07D1Phase 317 trials
Sichuan Baili Pharmaceutical Co., Ltd. · HER2-positive Breast Cancer, Non-squamous Non-small Cell Lung Cancer, Her2-positive/Low-expression Urinary and Digestive Tract Tumors
- Telisotuzumab AdizutecanABBV-400Phase 316 trials
AbbVie · c-MET, Non-Squamous Non-Small Cell Lung Cancer, Metastatic Colorectal Cancer
- PD-1 monoclonal antibodyPhase 39 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Nasopharyngeal Carcinoma (NPC), Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma
- TucidinostatChidamide, HBI-8000Phase 39 trials
Chipscreen Biosciences, Ltd. · Relapsed/Refractory PTCLT With at Least One Line of Prior Systemic Therapy, Unresectable or Metastatic Melanoma, Progressive Brain Metastasis
- PD-1 inhibitorPhase 38 trials
BioAtla, Inc. · Advanced Solid Tumors, Gastric or Gastroesophageal Junction Adenocarcinoma, NSCLC (Advanced Non-small Cell Lung Cancer)
- IBI363Phase 37 trials
Innovent Biologics (Suzhou) Co. Ltd. · Melanoma, Colorectal Cancer, Resectable Stage II-III Non-small Cell Lung Cancer
- Supportive care measuresPhase 36 trials
Merck & Co. · Esophageal Squamous Cell Carcinoma, Metastatic Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma
- DarovasertibIDE 196, LXS196Phase 35 trials
IDEAYA Biosciences · Uveal Melanoma, Metastatic Uveal Melanoma, Cutaneous Melanoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.